55 related articles for article (PubMed ID: 16581969)
1. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells.
Yeung D; Zablocki K; Lien CF; Jiang T; Arkle S; Brutkowski W; Brown J; Lochmuller H; Simon J; Barnard EA; Górecki DC
FASEB J; 2006 Apr; 20(6):610-20. PubMed ID: 16581969
[TBL] [Abstract][Full Text] [Related]
2. Lectin-binding characterizes the healthy human skeletal muscle glycophenotype and identifies disease-specific changes in dystrophic muscle.
McMorran BJ; Miceli MC; Baum LG
Glycobiology; 2017 Dec; 27(12):1134-1143. PubMed ID: 28973355
[TBL] [Abstract][Full Text] [Related]
3. The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies.
Zabłocki K; Górecki DC
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298386
[TBL] [Abstract][Full Text] [Related]
4. Primary mouse myoblast metabotropic purinoceptor profiles and calcium signalling differ with their muscle origin and are altered in mdx dystrophinopathy.
Róg J; Oksiejuk A; Górecki DC; Zabłocki K
Sci Rep; 2023 Jun; 13(1):9333. PubMed ID: 37291185
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Dystrophin Expression Occurs across Diverse Tumors, Correlates with the Age of Onset, Staging and Reduced Survival of Patients.
Alnassar N; Borczyk M; Tsagkogeorga G; Korostynski M; Han N; Górecki DC
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900171
[TBL] [Abstract][Full Text] [Related]
6. P2 Receptor Signaling in Motor Units in Muscular Dystrophy.
Khairullin AE; Grishin SN; Ziganshin AU
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675094
[TBL] [Abstract][Full Text] [Related]
7. Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts.
Gosselin MRF; Mournetas V; Borczyk M; Verma S; Occhipinti A; Róg J; Bozycki L; Korostynski M; Robson SC; Angione C; Pinset C; Gorecki DC
Elife; 2022 Sep; 11():. PubMed ID: 36164827
[TBL] [Abstract][Full Text] [Related]
8. P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH; Róg J; Chira N; Kao AP; Al-Khalidi R; Górecki DC
Front Pharmacol; 2022; 13():935804. PubMed ID: 35910348
[TBL] [Abstract][Full Text] [Related]
9. P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy.
Raffaghello L; Principi E; Baratto S; Panicucci C; Pintus S; Antonini F; Del Zotto G; Benzi A; Bruzzone S; Scudieri P; Minetti C; Gazzerro E; Bruno C
Pharmaceuticals (Basel); 2022 Jan; 15(1):. PubMed ID: 35056146
[TBL] [Abstract][Full Text] [Related]
10. Disrupted Calcium Homeostasis in Duchenne Muscular Dystrophy: A Common Mechanism behind Diverse Consequences.
Zabłocka B; Górecki DC; Zabłocki K
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681707
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Spatial and Temporal Distribution of Purinergic P2 Receptors in the Mouse Hippocampus.
Lommen J; Detken J; Harr K; von Gall C; Ali AAH
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360844
[TBL] [Abstract][Full Text] [Related]
12. eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases.
Panicucci C; Raffaghello L; Bruzzone S; Baratto S; Principi E; Minetti C; Gazzerro E; Bruno C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825102
[TBL] [Abstract][Full Text] [Related]
13. P2X7 Receptor in the Management of Energy Homeostasis: Implications for Obesity, Dyslipidemia, and Insulin Resistance.
Coccurello R; Volonté C
Front Endocrinol (Lausanne); 2020; 11():199. PubMed ID: 32528404
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.
Miyatake S; Shimizu-Motohashi Y; Takeda S; Aoki Y
Drug Des Devel Ther; 2016; 10():2745-58. PubMed ID: 27621596
[TBL] [Abstract][Full Text] [Related]
15. Dystrophin: The dead calm of a dogma.
Górecki DC
Rare Dis; 2016; 4(1):e1153777. PubMed ID: 27141413
[TBL] [Abstract][Full Text] [Related]
16. Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis.
Cea LA; Puebla C; Cisterna BA; Escamilla R; Vargas AA; Frank M; Martínez-Montero P; Prior C; Molano J; Esteban-Rodríguez I; Pascual I; Gallano P; Lorenzo G; Pian H; Barrio LC; Willecke K; Sáez JC
Cell Mol Life Sci; 2016 Jul; 73(13):2583-99. PubMed ID: 26803842
[TBL] [Abstract][Full Text] [Related]
17. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
[TBL] [Abstract][Full Text] [Related]
18. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN; Sinadinos A; Lefebvre A; Chan P; Arkle S; Vaudry D; Gorecki DC
Autophagy; 2015; 11(1):113-30. PubMed ID: 25700737
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
